CIBMTR Reporting Implementation Guide
0.1.6 - Trial Use 1
CIBMTR Reporting Implementation Guide
0.1.6 - Trial Use 1
This page is part of the CIBMTR Reporting Implementation Guide (v0.1.6: Release Draft) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions 
Generated Narrative: MedicationRequest
Resource MedicationRequest "MedicationRequest-Etoposide-Example"
Profile: CIBMTR Medication Request (mcode)
Security Labels: http://terminology.cibmtr.org/codesystem/transplant-center
status: active
intent: order
medication: Medication/Medication-Etoposide-Example: etoposide (VEPESID) chemo IVPB
subject: Patient/PatientExample6 ""
authoredOn: 2020-07-21 14:17:00+0000
requester: : unknown
reasonCode: Cancer (CMS/HCC) (SNOMED CT#363346000 "Malignant neoplastic disease (disorder)"; International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)#C80.1 "Malignant (primary) neoplasm, unspecified")
dosageInstruction
text: 68 mg (100 mg/m2 x 0.68 m2 Treatment plan actual BSA), Intravenous, for 60 Minutes, Every 24 hours, First dose on Tue 11/19/13 at 0000, For 5 doses Give after CISplatin and mannitol.
timing: Code: Every 24 hours, Starting 2020-07-22 16:58:05+0000, Count 5 times, Duration 60hours, Once per 24 hours, Until 2020-07-22 16:58:05+0000
asNeeded: false
route: Intravenous central route (qualifier value) (SNOMED CT#418114005)
doseAndRate
doseAndRate